Evidence map›Paper›PMID 40707132›Full record

ArticleJournal for immunotherapy of cancer2025

Constitutive IL-7 signaling promotes CAR-NK cell survival in the solid tumor microenvironment but impairs tumor control.

Matthew Dysthe, Ishwar Navin, Dayenne van Leeuwen, Josue Pineda, Corrine Baumgartner, Cliona M Rooney, Robin Parihar

Abstract read
In one paragraph

Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Matthew DystheTranslational Biology and Molecular Medicine, Baylor College of Medicine, Houston, Texas, USA.
Ishwar NavinImmunology and Microbiology, Baylor College of Medicine, Houston, Texas, USA.
Dayenne van LeeuwenImmunology and Microbiology, Baylor College of Medicine, Houston, Texas, USA.
Josue PinedaPediatrics-Oncology, Baylor College of Medicine, Houston, Texas, USA.
Corrine BaumgartnerPediatrics-Oncology, Baylor College of Medicine, Houston, Texas, USA.
Cliona M RooneyTranslational Biology and Molecular Medicine, Baylor College of Medicine, Houston, Texas, USA.ORCID http://orcid.org/0000-0003-3210-2864
Robin PariharTranslational Biology and Molecular Medicine, Baylor College of Medicine, Houston, Texas, USA rparihar@bcm.edu.ORCID http://orcid.org/0000-0002-3283-6713

Funding

HSRD VA SDR 16-196
6 · The paper itself

Abstract

backgroundAdoptive transfer of chimeric antigen receptor (CAR)-expressing natural killer (NK) cells has demonstrated success against hematological malignancies. Efficacy against solid tumors has been limited by poor NK cell survival and function in the suppressive tumor microenvironment (TME). To enhance efficacy against solid tumors, stimulatory cytokines have been incorporated into CAR-NK cell therapeutic approaches. However, current cytokine strategies have limitations, including systemic toxicities, exogenous dependencies, and unwanted TME bystander effects. Here, we aimed to overcome these limitations by modifying CAR-NK cells to express a constitutively active interleukin (IL)-7 receptor, termed C7R, capable of providing intrinsic CAR-NK cell activation that does not rely on or produce exogenous signals nor activate bystander cells.

methodsWe examined persistence, antitumor function, and transcriptional profiles of CAR-NK cells coexpressing C7R in a novel tumor immune microenvironment (TiME) co-culture system and against hematologic and solid tumor xenografts in vivo.

resultsPeripheral blood NK cells expressing a CAR directed against the solid tumor antigen GD2 and modified with C7R demonstrated enhanced tumor killing and persistence in vitro compared with CAR-NK cells without cytokine support and similar functions to CAR-NK cells supplemented with recombinant IL-15. C7R.CAR-NK cells exhibited enhanced survival and proliferation within neuroblastoma TiME xenografts in vivo but produced poor long-term tumor control compared with CAR-NK cells supplemented with IL-15. Similar results were seen using C7R-expressing CD19.CAR-NK cells against CD19+leukemia xenografts. Gene expression analysis revealed that chronic signaling via C7R induced a transcriptional signature consistent with intratumor stressed NK cells with blunted effector function. We identified gene candidates associated with chronic cytokine-stressed NK cells that could be targeted to reduce CAR-NK cell stress within the solid TME.

conclusionC7R promoted CAR-NK cell survival in hostile TMEs independent of exogenous signals but resulted in poor antitumor function in vivo. Our data reveals the detrimental role of continuous IL-7 signaling in CAR-NK cells and provides insights into proper application of cytokine signals when attempting to enhance CAR-NK cell antitumor activity.

Indexed as

Immunotherapy, AdoptiveInterleukin-7Killer Cells, NaturalNeoplasmsReceptors, Chimeric AntigenTumor MicroenvironmentAnimalsCell Line, TumorCell SurvivalHumansMiceSignal TransductionXenograft Model Antitumor AssaysIL7 protein, humanInterleukin-7Receptors, Chimeric AntigenAdoptive cell therapy - ACTChimeric antigen receptor - CARCytokineNatural killer - NKTumor microenvironment - TME

Identifiers

PMID40707132
PMCPMC12315002

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.